Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZBIO Zenas BioPharma Inc.

Closed 01-26 16:00:00 EST

19.32

-0.77

-3.83%

盘后19.40

+0.08+0.41%

19:45 EST

High19.84	Low19.00	Vol433.25K
Open19.80	D1 Closing20.09	Amplitude4.18%
Mkt Cap1.04B	Tradable Cap407.11M	Total Shares53.68M
T/O8.36M	T/O Rate2.06%	Tradable Shares21.07M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":19.32,"timestamp":1769461200000,"preClose":20.09,"halted":0,"volume":433253,"hourTrading":{"tag":"盘后","latestPrice":19.4,"preClose":19.32,"latestTime":"19:45 EST","volume":2905,"amount":56107.06,"timestamp":1769474713751,"change":0.08,"changeRate":0.004141,"amplitude":0.010352},"delay":0,"changeRate":-0.03832752613240416,"floatShares":21071865,"shares":53679166,"eps":-4.527832,"marketStatus":"Closed","change":-0.77,"latestTime":"01-26 16:00:00 EST","open":19.8,"high":19.84,"low":19,"amount":8360349.699076,"amplitude":0.041812,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.527832,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769504400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":20.09,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":19.75,"preClose":20.09,"latestTime":"09:29 EST","volume":1204,"amount":23934.458071999998,"timestamp":1769437799911,"change":-0.34,"changeRate":-0.016924,"amplitude":0.017422},"postHourTrading":{"tag":"盘后","latestPrice":19.4,"preClose":19.32,"latestTime":"19:45 EST","volume":2905,"amount":56107.06,"timestamp":1769474713751,"change":0.08,"changeRate":0.004141,"amplitude":0.010352},"volumeRatio":0.600139,"impliedVol":1.2023,"impliedVolPercentile":0.7907},"requestUrl":"/m/hq/s/ZBIO/wiki","defaultTab":"wiki","newsList":[{"id":"2604919949","title":"Zenas BioPharma Grants Stock Options to New Employee Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919949","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919949?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:15","pubTimestamp":1768598107,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. has granted a newly hired employee non-qualified stock options to purchase 100,000 shares of the company’s common stock at an exercise price of $19.93 per share, matching the closing price on January 15, 2026. The options have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary of the employee’s start date and the remainder vesting in 36 equal monthly installments, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on January 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL9BbqzD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","SG9999014005.SGD","BK4588","SG9999014013.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ","BK4112","LU2210150020.SGD","ZBIO","LU2210149790.SGD","IE00BGHQF748.EUR","BK4139","SG9999014039.USD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2604182919","title":"Zenas Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604182919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604182919?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:15","pubTimestamp":1768598100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nTUA8WWJBB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2604919470","title":"Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919470","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919470?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:15","pubTimestamp":1768598100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Jan.  16, 2026  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/16/3220558/0/en/Zenas-BioPharma-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2602510429","title":"Zenas Biopharma Unveils Pipeline Strategy Targeting Autoimmune and Multiple Sclerosis Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510429","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510429?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:13","pubTimestamp":1768223631,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. has released a corporate presentation outlining its progress and pipeline in the field of autoimmune diseases. The company highlighted plans for global marketing submissions for obexelimab in IgG4-related disease  and noted two late-stage franchise programs spanning four indications in immunology and inflammation (I&I). Additionally, two early-stage programs with best-in-class potential are in development, including an oral IL-17AA/AF inhibitor  and a brain-penetrant TYK2 inhibitor , both expected to enter Phase 1 trials. Zenas also reported achievement of primary and key secondary endpoints in the INDIGO Phase 3 IgG4-RD trial and shared data from the MoonStone Phase 2 relapsing multiple sclerosis trial. The company is positioning itself as a global, fully-integrated biopharmaceutical entity with commercial presence across multiple therapeutic areas, including rheumatology, multiple sclerosis, and dermatology. You can access the full presentation through the link b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL7c02lQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2602580617","title":"Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet","url":"https://stock-news.laohu8.com/highlight/detail?id=2602580617","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602580617?lang=en_us&edition=fundamental","pubTime":"2026-01-10 22:01","pubTimestamp":1768053660,"startTime":"0","endTime":"0","summary":"The Benzinga Stock Whisper Index highlights five stocks seeing stronger than normal interest from readers and looks at the potential catalysts driving the attention.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/10/Stock-Whisper-Index.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/10/Stock-Whisper-Index.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/long-ideas/26/01/49829288/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-96","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/26/01/49829288/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-96","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","BK4548","LU0788109048.HKD","LU2125910500.SGD","LU0265267285.USD","LU0143863784.USD","NIO.SI","LU1861220207.SGD","BK4581","IE00B1B80R65.USD","LU0196696453.USD","MNTS","BK4574","LU0449509016.USD","BK4555","BK4099","LU0251143458.SGD","LU0708995583.HKD","LU0823046494.USD","LU1868838027.USD","LU0214875030.USD","NU","BK4535","BK4549","IE00BGV7N243.SGD","BK4211","LU1861217088.USD","LU0823046577.USD","09866","BK4504","BK4531","BK4526","BK4585","LU0531970944.HKD","GB00BDT5M118.USD","BK4505","BK4534","LU0265266980.USD","LU0396314238.USD","LU2045819591.USD","LU0531971322.HKD","SOFI","BK4509","LU0052750758.USD","EVS.SI","LU0256859116.SGD","LU1868837565.USD","BK4588","LU0196696701.USD","LU0050427557.USD","LU0072463663.USD","LU0143863198.USD","LU0254981946.USD","LU0572108347.SGD","BK4187","LU0048575426.USD","LU2360107671.USD","BK4559","BK4207","NIO","BK4166","ZBIO","LU0456842615.SGD","LU0053687314.USD","LU1481012133.USD","LU0086394185.USD","LU0261950470.USD","BK4551","LU0210535034.USD","LU0106259046.USD","LU0320764599.SGD","BK4532"],"gpt_icon":1},{"id":"2602304583","title":"Zenas Biopharma CEO Leon O. Moulder Jr. Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602304583","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602304583?lang=en_us&edition=fundamental","pubTime":"2026-01-10 10:43","pubTimestamp":1768013018,"startTime":"0","endTime":"0","summary":"Leon O. Moulder Jr., Chief Executive Officer of Zenas Biopharma Inc., reported the acquisition of common shares of Zenas Biopharma Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260110:nNDL79SP5f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Zenas Biopharma CEO Leon O. Moulder Jr. Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2601920258","title":"Morgan Stanley Downgrades Zenas BioPharma to Equalweight From Overweight, Adjusts Price Target to $19 From $37","url":"https://stock-news.laohu8.com/highlight/detail?id=2601920258","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601920258?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:56","pubTimestamp":1767704175,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO) has an average rating of buy and mean price target of $40.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO"],"gpt_icon":0},{"id":"2601929878","title":"Why Zenas BioPharma's Selloff Was Structurally Inevitable","url":"https://stock-news.laohu8.com/highlight/detail?id=2601929878","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601929878?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:38","pubTimestamp":1767703080,"startTime":"0","endTime":"0","summary":"Zenas BioPharma  shares fell more than 50% in the last trading session following the release of Phase 3 results for obexelimab in patients with immunoglobulin G4-related disease .While the trial demonstrated a meaningful reduction in flare risk, efficacy metrics fell short of market expectations, triggering a sharp repricing in the stock. However, when viewed through the Adhishthana framework, this decline appears far from surprising. The stock's cyclical positioning had already signaled elevated risk, offering clarity on why the selloff unfolded so aggressively and what may lie ahead.In Zenas' case, the stock began Phase 2 by rallying sharply during the Sankhya window. This behaviour represents a clear deviation from the expected structure. Historically, rallies that emerge prematurely during Sankhya tend to be unstable and are often corrected swiftly once reality sets in.For now, increasing exposure would be premature. A more prudent approach would be to wait for the st","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/06/ZBio-Phase-2-Chart-Adhishthana.png?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/06/ZBio-Phase-2-Chart-Adhishthana.png?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/26/01/49718715/why-zenas-biopharmas-selloff-was-structurally-inevitable","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/26/01/49718715/why-zenas-biopharmas-selloff-was-structurally-inevitable","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2601914855","title":"A Look At Zenas BioPharma (ZBIO) Valuation After Recent Volatility And Premium Price To Book Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2601914855","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601914855?lang=en_us&edition=fundamental","pubTime":"2026-01-06 06:15","pubTimestamp":1767651315,"startTime":"0","endTime":"0","summary":"What Zenas BioPharma’s recent performance tells you\nZenas BioPharma (ZBIO) has been on many watchlists after a sharp move in its share price over the past 3 months, even as shorter term returns over the past week and month have been negative.\nFor context, the stock closed at US$34.50, with a 1 day return of about 5% decline, a 7 day return of roughly 11.7% decline, and a month return of about 12.4% decline, while the past 3 months show a gain above 65%.\nIf you are looking at this recent...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/a-look-at-zenas-biopharma-zbio-valuation-after-recent-volati","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/a-look-at-zenas-biopharma-zbio-valuation-after-recent-volati","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2601831965","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2601831965","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601831965?lang=en_us&edition=fundamental","pubTime":"2026-01-06 03:00","pubTimestamp":1767639627,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO) reported Monday that a phase 3 trial of obexelimab in immunoglobulin G4-related disease showed a 56% reduction in the risk of disease flare.However, Amgen (AMGN) had won approva","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4566","LU2242646821.SGD","SG9999018865.SGD","LU1169590202.USD","LU1571399168.USD","SG9999014880.SGD","SG9999014906.USD","LU2468319806.SGD","BK4588","SG9999017495.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4533","LU2242652126.USD","LU1057294990.SGD","SG9999014898.SGD","IE0009355771.USD","LU0109394709.USD","BK4581","LU0868494617.USD","BK4512","LU1023059063.AUD","IE00B2B36J28.USD","SG9999014914.USD","IE00BJJMRZ35.SGD","ZBIO","SGXZ31699556.SGD","AMGN","LU1814569148.SGD","BK4585","LU1983299246.USD","BK4534","BK4599","BK4139","SLRX","IE0002141913.USD","DCOY","LU0889565916.HKD","SG9999018857.SGD","LU0122379950.USD","SG9999001440.SGD","LU2089984988.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU2112291526.USD","LU1861220033.SGD","BK4145","LU1861215975.USD","JBL"],"gpt_icon":0},{"id":"2601381818","title":"Zenas Biopharma Shares Hit More Than Four-Month Low After Late-Stage Data for Immune Disorder Drug, Last Down 55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601381818","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601381818?lang=en_us&edition=fundamental","pubTime":"2026-01-05 23:26","pubTimestamp":1767626785,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL4N3Y614E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2601881083","title":"Zenas BioPharma's immune disorder drug meets main goal in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601881083","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601881083?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:25","pubTimestamp":1767619514,"startTime":"0","endTime":"0","summary":"In 2023, the drugmaker partnered with Bristol Myers Squibb ZBIO.O, which holds exclusive rights to develop and market obexelimab in Japan, South Korea, Taiwan, Hong Kong, Singapore and Australia.  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL4N3Y60T6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","LU0109394709.USD","LU0289739699.SGD","LU1989771016.USD","LU2125154935.USD","LU0061475181.USD","LU2360032135.SGD","LU0225771236.USD","BK4532","BK4581","BK4599","LU1323610961.USD","AMGN","ZBIO","LU1670711040.USD","LU2242646821.SGD","BK4559","LU0058720904.USD","LU2089984988.USD","LU1868837136.USD","LU0321505439.SGD","IE0009355771.USD","LU0096364046.USD","LU0868494617.USD","LU2133065610.SGD","IE00BFTCPJ56.SGD","LU0985481810.HKD","LU1670710588.SGD","IE00BJJMRZ35.SGD","LU0306806265.USD","LU2242652126.USD","BK4533","LU1670711123.USD","LU1868836757.USD","BK4007","LU0320765992.SGD","LU1868836591.USD","LU0267386448.USD","LU1585245621.USD","LU1983299246.USD","IE00BFXG1179.USD","LU1670710661.SGD","LU1868837300.USD","LU2125154778.USD","BK4588","IE00BSNM7G36.USD","BMY","SG9999001440.SGD","LU0321505868.SGD"],"gpt_icon":0},{"id":"2601487881","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2601487881","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601487881?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:15","pubTimestamp":1767618944,"startTime":"0","endTime":"0","summary":"Zenas BioPharma  shares were down 52% in recent Monday premarket activity, extending Friday's loss.XPeng  shares were down 3.3%, shaving the previous session's gain.Baidu  stock was 2.9% lower, erasing Friday's increase.GSK  stock was 1.8% lower, after Friday's gain.AutoZone  shares were down 1.3% after Mizuho Securities downgraded the company's stock to neutral from outperform and lowered its price target to $3,550 from $3,850.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4099","LU0345770308.USD","LU0359201612.USD","LU1221951046.USD","BK4585","BK4555","BK4552","BK4543","LU0053666078.USD","LU0965509010.AUD","LU1221951129.SGD","BK4007","BK4574","BK4587","LU1032955483.USD","BK4139","BK4551","ZBIO","LU2463526074.USD","BK4548","LU0965509283.SGD","IE00B0JY6N72.USD","AZO","LU1829250122.USD","BK4505","BK4531","LU1934455277.USD","GSK.UK","LU1037948897.HKD","LU1571399168.USD","LU1196500208.SGD","LU0965509101.SGD","BK4504","BK4579","LU1934455863.HKD","BK4214","BK4077","BK4602","LU1115378108.SGD","BK4535","BK4614","GSK","LU0234570918.USD","LU0287142896.SGD","LU1506573853.SGD","LU0965508806.USD","LU0314106906.USD","LU1037948541.HKD","LU1023057109.AUD","LU1934455194.USD","BK4588","BK4532","BK4612","LU0861579265.USD","EVS.SI","BK4514","LU0345770993.USD","LU0359202008.SGD","LU0640798160.USD","BK4526","LU0173614495.USD"],"gpt_icon":1},{"id":"2601325886","title":"Zenas Biopharma Reports Positive Phase 3 Results for Obexelimab in IgG4-Related Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2601325886","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601325886?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:05","pubTimestamp":1767614710,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. announced positive results from the Phase 3 INDIGO registrational trial of obexelimab in patients with Immunoglobulin G4-Related Disease . The study met its primary endpoint, demonstrating a 56% reduction in the risk of IgG4-RD flare, and achieved statistically significant results across all four key secondary efficacy endpoints. Obexelimab was reported to be well tolerated with no new safety signals observed. Zenas plans to submit a Biologics License Application  to the U.S. Food and Drug Administration  in the second quarter of 2026, and a Marketing Authorization Application  to the European Medicines Agency  in the second half of 2026. The results were presented during a conference call and webcast on January 5, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL92754p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","LU2210149790.SGD","BK4139","BK4588","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4585","NDAQ","LU2210150020.SGD","LU2095319765.USD","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2601988638","title":"Zenas Biopharma Inc - Obexelimab Meets All Four Secondary Efficacy Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2601988638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601988638?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:05","pubTimestamp":1767614700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA7PSXJY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2601886860","title":"Zenas Biopharma Announces Positive Results From Phase 3 Indigo Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (Igg4-Rd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601886860","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601886860?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:05","pubTimestamp":1767614700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA7PSXJY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2601886800","title":"Zenas Biopharma Inc - Plans Bla Submission to FDA in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601886800","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601886800?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:05","pubTimestamp":1767614700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA7PSXJY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2601886388","title":"Zenas Biopharma Inc - Obexelimab Achieves 56% Reduction in Igg4-Rd Flare Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2601886388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601886388?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:05","pubTimestamp":1767614700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA7PSXJY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2601886384","title":"Zenas Biopharma Inc: Obexelimab Was Well Tolerated and No New Safety Signals Were Observed","url":"https://stock-news.laohu8.com/highlight/detail?id=2601886384","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601886384?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:05","pubTimestamp":1767614700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA7PSXJY:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2601372886","title":"Zenas Biopharma Inc:  Anticipates Submitting a Maa to Ema in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601372886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601372886?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:05","pubTimestamp":1767614700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA7PSXJY:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zenasbio.com","stockEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.5346},{"period":"3month","weight":-0.1592},{"period":"6month","weight":0.2829},{"period":"1year","weight":1.3974},{"period":"ytd","weight":-0.4467}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.066193},{"month":2,"riseRate":0.4,"avgChangeRate":-0.014847},{"month":3,"riseRate":0.6,"avgChangeRate":-0.027723},{"month":4,"riseRate":0.5,"avgChangeRate":0.001823},{"month":5,"riseRate":0.75,"avgChangeRate":0.218705},{"month":6,"riseRate":0.25,"avgChangeRate":-0.082782},{"month":7,"riseRate":0.2,"avgChangeRate":-0.126333},{"month":8,"riseRate":0.6,"avgChangeRate":0.033743},{"month":9,"riseRate":0.5,"avgChangeRate":0.044898},{"month":10,"riseRate":0.6,"avgChangeRate":0.128289},{"month":11,"riseRate":0,"avgChangeRate":-0.164546},{"month":12,"riseRate":0.4,"avgChangeRate":0.053544}],"exchange":"NASDAQ","name":"Zenas BioPharma Inc.","nameEN":"Zenas BioPharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zenas BioPharma Inc.(ZBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zenas BioPharma Inc.,ZBIO,Zenas BioPharma Inc.股票,Zenas BioPharma Inc.股票老虎,Zenas BioPharma Inc.股票老虎国际,Zenas BioPharma Inc.行情,Zenas BioPharma Inc.股票行情,Zenas BioPharma Inc.股价,Zenas BioPharma Inc.股市,Zenas BioPharma Inc.股票价格,Zenas BioPharma Inc.股票交易,Zenas BioPharma Inc.股票购买,Zenas BioPharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zenas BioPharma Inc.(ZBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}